Literature DB >> 14999464

[Annual costs of bipolar disorders in Germany].

C Runge1, H Grunze.   

Abstract

With costs of approximately 5.8 billion EUR annually, bipolar disorders represent a substantial burden on German society. The costs are mainly due to high indirect costs caused by morbidity-related unemployment, suicide-related losses of productivity, time off from work, and early retirement. Inpatient care, with a considerable average length of stay for patients with bipolar disorders, accounts for two-thirds of direct costs. This paper refers to statistics on use of healthcare services based primarily on the International Statistical Classification of Diseases, Tenth Revision. Representing a relatively narrow definition of bipolar disorders in comparison with the clinically relevant spectrum, this classification leads to a conservative estimate of the total costs. The significant lag between first acute episode and a correct diagnosis causes a delayed onset of maintenance treatment that leads to increased costs. Increasing public awareness, destigmatizing the disease, and educating physicians are necessary steps to limit the substantial economic burden for society.

Entities:  

Mesh:

Year:  2004        PMID: 14999464     DOI: 10.1007/s00115-004-1691-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  25 in total

1.  Cross-national epidemiology of major depression and bipolar disorder.

Authors:  M M Weissman; R C Bland; G J Canino; C Faravelli; S Greenwald; H G Hwu; P R Joyce; E G Karam; C K Lee; J Lellouch; J P Lépine; S C Newman; M Rubio-Stipec; J E Wells; P J Wickramaratne; H Wittchen; E K Yeh
Journal:  JAMA       Date:  1996 Jul 24-31       Impact factor: 56.272

2.  The economic burden of bipolar disease.

Authors:  S W Woods
Journal:  J Clin Psychiatry       Date:  2000       Impact factor: 4.384

Review 3.  Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants?

Authors:  H J Möller; H Grunze
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2000       Impact factor: 5.270

4.  Manic depression: do people receive adequate support?

Authors:  G Shepherd; R G Hill
Journal:  Nurs Times       Date:  1996 Jun 26-Jul 2

5.  The Stanley Foundation Bipolar Network. 2. Preliminary summary of demographics, course of illness and response to novel treatments.

Authors:  R W Kupka; W A Nolen; L L Altshuler; K D Denicoff; M A Frye; G S Leverich; P E Keck; S L McElroy; A J Rush; T Suppes; R M Post
Journal:  Br J Psychiatry Suppl       Date:  2001-06

6.  [Affective, somatoform and anxiety disorders in Germany--initial results of an additional federal survey of "psychiatric disorders"].

Authors:  H U Wittchen; N Müller; H Pfister; S Winter; B Schmidtkunz
Journal:  Gesundheitswesen       Date:  1999-12

Review 7.  Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders.

Authors:  H S Akiskal; M L Bourgeois; J Angst; R Post; H Möller; R Hirschfeld
Journal:  J Affect Disord       Date:  2000-09       Impact factor: 4.839

Review 8.  What is to be done? Controversies in the diagnosis and treatment of manic-depressive illness.

Authors:  N Ghaemi; G S Sachs; F K Goodwin
Journal:  World J Biol Psychiatry       Date:  2000-04       Impact factor: 4.132

9.  Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program.

Authors:  Jinmei Li; Jeffrey S McCombs; Glen L Stimmel
Journal:  J Affect Disord       Date:  2002-09       Impact factor: 4.839

Review 10.  The effect of prophylactic lithium treatment on mortality and suicidal behavior: a review for clinicians.

Authors:  M Schou
Journal:  J Affect Disord       Date:  1998-09       Impact factor: 4.839

View more
  7 in total

Review 1.  A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder.

Authors:  Ifigeneia Mavranezouli; Joran Lokkerbol
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

Review 2.  Quetiapine: a pharmacoeconomic review of its use in bipolar disorder.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

3.  The cost of relapse for patients with a manic/mixed episode of bipolar disorder in the EMBLEM study.

Authors:  Jihyung Hong; Catherine Reed; Diego Novick; Josep Maria Haro; Frank Windmeijer; Martin Knapp
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 4.  Cost-of-illness studies for bipolar disorder: systematic review of international studies.

Authors:  Huajie Jin; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

Review 5.  The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines.

Authors:  Konstantinos N Fountoulakis; Allan Young; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Pierre Blier; Hans Jurgen Moeller; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 6.  Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health.

Authors:  Peter Falkai; Nikolaos Koutsouleris; Katja Bertsch; Mirko Bialas; Elisabeth Binder; Markus Bühner; Alena Buyx; Na Cai; Silvia Cappello; Thomas Ehring; Jochen Gensichen; Johannes Hamann; Alkomiet Hasan; Peter Henningsen; Stefan Leucht; Karl Heinz Möhrmann; Elisabeth Nagelstutz; Frank Padberg; Annette Peters; Lea Pfäffel; Daniela Reich-Erkelenz; Valentin Riedl; Daniel Rueckert; Andrea Schmitt; Gerd Schulte-Körne; Elfriede Scheuring; Thomas G Schulze; Rudolf Starzengruber; Susanne Stier; Fabian J Theis; Juliane Winkelmann; Wolfgang Wurst; Josef Priller
Journal:  Front Psychiatry       Date:  2022-03-04       Impact factor: 4.157

7.  Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study.

Authors:  Susanne Kraemer; Anette Minarzyk; Steffen Eppendorfer; Carsten Henneges; Hans-Peter Hundemer; Stefan Wilhelm; Heinz Grunze
Journal:  BMC Psychiatry       Date:  2013-07-17       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.